Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New dialysis needle aims to improve safety for kidney patients

NCT ID NCT05927532

Disease control Sponsor: Mozarc Medical US LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a new dialysis needle called the Argyle Safety Fistula Cannula with an anti-reflux valve. It was used in 40 adults with end-stage kidney failure who get dialysis three times a week for 12 weeks. The goal was to see if the needle is safe and works well for hemodialysis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Argyle Safety Fistula Cannula with Anti-Reflux Valve (a specialized dialysis needle)
What this could lead to
If successful, this cannula could make dialysis sessions safer and more reliable for people with kidney failure.
What could go wrong
This is a small, early-stage study with only 40 participants and no comparison group, so results may not apply to everyone. The device is already on the market in some regions, so the novelty is limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Mar 2024

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject who is aged 18 years or older who signed informed consent * Subject is undergoing in-center hemodialysis * Subject has an arteriovenous fistulae (AVF) fistula that was determined to be mature by standard clinical definition Exclusion Criteria: * Subject is enrolled in another study that could confound the results of this study, without documented pre-approval * Subject with an existing arteriovenous graft * Subjects with known allergies to plastics * Subjects who are unable to read or respond to the questionnaire about satisfaction

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End stage renal failure on dialysis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End stage renal failure on dialysis

Contacts and locations

Locations

  • DaVita Columbus

    Columbus, Georgia, 31904, United States

  • DaVita Hartford

    Hartford, Connecticut, 06082, United States

  • DaVita Norfolk

    Norfolk, Virginia, 23505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.